Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Genomic Vision S.A.. (5/23/17). "Press Release: Genomic Vision to Enter into Technological Collaboration with AstraZeneca in Oncology". Bagneux.

Organisations Organisation Genomic Vision S.A. (Euronext Paris: GV)
  Organisation 2 AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
Products Product molecular combing technology
  Product 2 WEE1 kinase inhibitor
Index term Index term AstraZeneca–Genomic Vision: genomic technology, 201705– collab using FiberVision DNA combing to develop WEE1 kinase inhibitors
Persons Person Bensimon, Aaron (Genomic Vision 201107 CEO + founder)
  Person 2 Arabian, Bruno (Ulysse Communication 201807 before Milestones 201511)

The FiberVision® platform will test the impact of a WEE1 kinase inhibitor on DNA replication in cancer cells.

Genomic Vision (FR0011799907 – GV), a company specialized in the development of diagnostic tests (IVD) for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), today announced that they have entered into a technological collaboration with AstraZeneca in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.

Through the use of FiberVision®, the DNA molecular combing platform of Genomic Vision, AstraZeneca will evaluate the impact of the WEE1 kinase inhibitor on DNA replication progression in cancer cells and how the induction of replication stress contributes to its anti-tumour efficacy in specific cancer genetic backgrounds.

Molecular combing should allow a comprehensive characterisation of the different replication stress effects induced by the WEE1 inhibitors. Wider profiling using the platform will also be carried out to enable mechanistic differentiation between DDR inhibitors within the AstraZeneca portfolio. The in-depth scientific understanding of replication stress obtained by the innovative molecular combing platform could support the development of new personalised medicine opportunities for DDR inhibitors.

Aaron Bensimon, CEO of Genomic Vision, declared: “This collaboration agreement on the use of the molecular combing by AstraZeneca, one of the most innovative companies in the research of novel anti-cancer agents, represents a strong recognition of our technology added value. Initially used for the development of diagnostic tests, molecular combing indeed offers substantial outlooks to accelerate the selection and optimization process of high potential therapeutic compounds for the treatment of cancer.”


GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing the identification of genetic abnormalities, GENOMIC VISION supports the R&D productivity of pharmaceutical companies, leaders in the diagnostic industry and research labs.

The Company develops a strong portfolio of diagnostic tests (breast and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based in Bagneux, near Paris, the Company employs approximately 60 people. GENOMIC VISION is a public company listed on compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit


Genomic Vision
Aaron Bensimon
Co-fondateur et Président du Directoire
Tél. : +33 1 49 08 07 50

Press Relations
Bruno Arabian
Tel. : +33 1 83 62 34 84

Investor Relations
Dušan Orešanský / Emmanuel Huynh
Tel. : +33 1 44 71 94 92

Membre des indices CAC® Mid & Small et CAC® All-Tradable


This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Record changed: 2023-06-05


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Genomic Vision S.A. (Euronext Paris: GV)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x300px

» top